norepinephrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
sympathomimetic, phenethyl derivatives	1960	51-41-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: norepinephrine (R)-Norepinephrine arterenol levarterenol noradrenaline norepinephrine bitartrate (-)-noradrenaline	Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Molecular weight: 169.18 Formula: C8H11NO3 CLOGP: -0.99 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 86.71 ALOGS: -1.13 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

norepinephrine
(R)-Norepinephrine
arterenol
levarterenol
noradrenaline
norepinephrine bitartrate
(-)-noradrenaline

Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic.

Molecular weight: 169.18
Formula: C8H11NO3
CLOGP: -0.99
LIPINSKI: 0
HAC: 4
HDO: 4
TPSA: 86.71
ALOGS: -1.13
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
6	mg	P

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	3 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
July 13, 1950	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	387.86	25.61	211	13909	52559	56225388
Hypotension	334.41	25.61	360	13760	250148	56027799
Septic shock	313.12	25.61	193	13927	60642	56217305
Cardiac arrest	292.34	25.61	211	13909	86103	56191844
Shock	291.53	25.61	131	13989	21597	56256350
Cardiogenic shock	266.41	25.61	113	14007	16212	56261735
Metabolic acidosis	202.03	25.61	126	13994	40328	56237619
Drug ineffective	177.95	25.61	567	13553	918422	55359525
Myoglobin urine present	169.02	25.61	37	14083	529	56277418
Stress cardiomyopathy	160.62	25.61	65	14055	8271	56269676
Peripheral ischaemia	160.42	25.61	55	14065	4408	56273539
Acute kidney injury	155.49	25.61	242	13878	240521	56037426
Intentional overdose	155.43	25.61	132	13988	67985	56209962
Fatigue	145.30	25.61	15	14105	788537	55489410
Renal failure	131.54	25.61	150	13970	110350	56167597
Toxicity to various agents	130.21	25.61	215	13905	224349	56053598
Respiratory failure	123.34	25.61	135	13985	94927	56183020
Circulatory collapse	122.34	25.61	72	14048	20731	56257216
Lactic acidosis	118.48	25.61	86	14034	35260	56242687
Haemodynamic instability	114.12	25.61	51	14069	8278	56269669
Renal injury	110.95	25.61	51	14069	8836	56269111
Electrocardiogram QRS complex prolonged	110.05	25.61	44	14076	5423	56272524
Pulseless electrical activity	109.17	25.61	47	14073	6977	56270970
Acute respiratory distress syndrome	108.65	25.61	68	14052	21858	56256089
Toxic encephalopathy	106.53	25.61	44	14076	5894	56272053
Vasoplegia syndrome	105.45	25.61	30	14090	1295	56276652
Serotonin syndrome	103.98	25.61	71	14049	26419	56251528
Ventricular tachycardia	103.35	25.61	60	14060	16841	56261106
Hyperlactacidaemia	93.41	25.61	32	14088	2556	56275391
Bradycardia	91.23	25.61	98	14022	67406	56210541
Amylase increased	90.95	25.61	39	14081	5732	56272215
Pharyngeal haemorrhage	89.82	25.61	22	14098	526	56277421
Propofol infusion syndrome	89.46	25.61	24	14096	831	56277116
Arthralgia	88.50	25.61	11	14109	501658	55776289
Pulmonary oedema	86.86	25.61	84	14036	51059	56226888
Headache	85.81	25.61	18	14102	559026	55718921
Nausea	85.20	25.61	43	14077	764135	55513812
Dry gangrene	85.11	25.61	21	14099	518	56277429
Troponin increased	84.74	25.61	42	14078	8593	56269354
Sepsis	79.68	25.61	133	13987	139707	56138240
Renal impairment	78.60	25.61	99	14021	80614	56197333
Ventricular hypokinesia	78.32	25.61	32	14088	4169	56273778
Atrioventricular block first degree	72.67	25.61	35	14085	6730	56271217
Extremity necrosis	71.72	25.61	23	14097	1495	56276452
Tachycardia	67.50	25.61	106	14014	105770	56172177
Ventricular fibrillation	67.26	25.61	39	14081	10913	56267034
Overdose	66.15	25.61	105	14015	105725	56172222
Fear	65.81	25.61	43	14077	14865	56263082
Blood lactate dehydrogenase increased	64.06	25.61	48	14072	20627	56257320
Acidosis	60.81	25.61	36	14084	10465	56267482
Electrocardiogram ST segment elevation	58.49	25.61	25	14095	3644	56274303
Alopecia	58.13	25.61	4	14116	293454	55984493
Pruritus	58.11	25.61	6	14114	316617	55961330
Blood creatine phosphokinase increased	57.28	25.61	51	14069	27901	56250046
Anuria	54.56	25.61	35	14085	11725	56266222
Alanine aminotransferase increased	54.53	25.61	90	14030	93572	56184375
Rash	54.41	25.61	28	14092	493019	55784928
Abdominal discomfort	54.28	25.61	4	14116	277270	56000677
Drug intolerance	54.28	25.61	3	14117	264815	56013132
Disseminated intravascular coagulation	54.25	25.61	41	14079	17844	56260103
Diabetes insipidus	53.90	25.61	21	14099	2416	56275531
Fall	53.76	25.61	12	14108	357498	55920449
Hyperkalaemia	52.06	25.61	64	14056	50801	56227146
Cardiotoxicity	51.70	25.61	29	14091	7621	56270326
Reversible cerebral vasoconstriction syndrome	50.87	25.61	20	14100	2357	56275590
Drug hypersensitivity	48.52	25.61	6	14114	275199	56002748
Systolic dysfunction	47.84	25.61	17	14103	1513	56276434
Anhedonia	47.22	25.61	30	14090	9884	56268063
Drug ineffective for unapproved indication	47.02	25.61	44	14076	25649	56252298
Blood potassium increased	46.75	25.61	37	14083	17224	56260723
Cardiomyopathy	46.52	25.61	36	14084	16222	56261725
Acid base balance abnormal	45.65	25.61	11	14109	245	56277702
Dizziness	45.10	25.61	19	14101	376121	55901826
Pain in extremity	44.66	25.61	10	14110	297421	55980526
Hypoxia	44.51	25.61	61	14059	53836	56224111
Nasopharyngitis	43.77	25.61	3	14117	220956	56056991
Cardio-respiratory arrest	43.28	25.61	61	14059	55260	56222687
Premature delivery	43.22	25.61	43	14077	27017	56250930
Electrocardiogram QT prolonged	42.42	25.61	60	14060	54528	56223419
Coagulopathy	42.07	25.61	36	14084	18680	56259267
Electrocardiogram ST segment depression	41.84	25.61	18	14102	2665	56275282
Left ventricle outflow tract obstruction	40.71	25.61	10	14110	242	56277705
Weight increased	40.49	25.61	5	14115	229698	56048249
Unmasking of previously unidentified disease	40.07	25.61	13	14107	877	56277070
Hypersensitivity	39.75	25.61	8	14112	256400	56021547
Infusion related reaction	38.20	25.61	4	14116	208927	56069020
Swelling	38.19	25.61	7	14113	239764	56038183
Unevaluable event	37.92	25.61	53	14067	47634	56230313
Distributive shock	37.47	25.61	13	14107	1078	56276869
Blood pressure decreased	37.43	25.61	59	14061	58991	56218956
Mydriasis	37.21	25.61	27	14093	11044	56266903
Diarrhoea	36.87	25.61	65	14055	638442	55639505
Injury	36.83	25.61	59	14061	59792	56218155
Constipation	36.58	25.61	4	14116	201939	56076008
Oliguria	36.41	25.61	24	14096	8416	56269531
Weight decreased	36.31	25.61	8	14112	240706	56037241
Diabetic macroangiopathy	35.93	25.61	8	14112	124	56277823
Back pain	35.53	25.61	8	14112	237162	56040785
Renal tubular necrosis	35.47	25.61	26	14094	10802	56267145
Wrong product administered	34.30	25.61	20	14100	5652	56272295
Activated partial thromboplastin time prolonged	33.98	25.61	21	14099	6591	56271356
Ischaemic hepatitis	33.21	25.61	14	14106	1971	56275976
Compartment syndrome	32.95	25.61	14	14106	2010	56275937
Suicide attempt	32.86	25.61	55	14065	57781	56220166
Patent ductus arteriosus	32.32	25.61	17	14103	3934	56274013
Torsade de pointes	32.26	25.61	26	14094	12414	56265533
Electrocardiogram repolarisation abnormality	32.08	25.61	12	14108	1235	56276712
Pain	31.90	25.61	75	14045	663109	55614838
Therapeutic product effect decreased	31.61	25.61	3	14117	169449	56108498
Malaise	31.03	25.61	28	14092	367832	55910115
Contraindicated product administered	30.61	25.61	5	14115	186281	56091666
Foetal exposure during pregnancy	30.55	25.61	40	14080	33783	56244164
Emotional distress	29.72	25.61	37	14083	29726	56248221
Premature baby	29.71	25.61	30	14090	19175	56258772
Insomnia	29.70	25.61	6	14114	191854	56086093
Encephalopathy	29.19	25.61	40	14080	35285	56242662
Ventricular extrasystoles	28.79	25.61	23	14097	10847	56267100
Supraventricular tachycardia	28.72	25.61	25	14095	13266	56264681
Off label use	28.44	25.61	237	13883	555943	55722004
Sinus bradycardia	28.24	25.61	25	14095	13561	56264386
Coma	27.79	25.61	52	14068	59603	56218344
Gait disturbance	27.71	25.61	4	14116	163317	56114630
Cardiovascular insufficiency	27.46	25.61	11	14109	1361	56276586
Thrombocytopenia	26.72	25.61	85	14035	136139	56141808
Peripheral swelling	26.32	25.61	13	14107	234713	56043234
Local anaesthetic systemic toxicity	26.19	25.61	9	14111	725	56277222
Hypothermia	26.03	25.61	23	14097	12447	56265500
Necrosis	25.95	25.61	16	14104	5000	56272947
Intestinal ischaemia	25.76	25.61	18	14102	6937	56271010

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	539.03	22.28	370	15991	67833	31613150
Cardiogenic shock	432.07	22.28	217	16144	22191	31658792
Drug ineffective	348.13	22.28	679	15682	394894	31286089
Appendicolith	301.97	22.28	113	16248	5618	31675365
Stress	269.46	22.28	165	16196	24776	31656207
Appendicitis	232.48	22.28	115	16246	11350	31669633
Septic shock	230.70	22.28	223	16138	65935	31615048
Shock	212.38	22.28	137	16224	22508	31658475
Hypotension	176.81	22.28	350	16011	204268	31476715
Sepsis	167.74	22.28	289	16072	151640	31529343
Ventricular fibrillation	164.40	22.28	109	16252	18739	31662244
Off label use	157.15	22.28	462	15899	346812	31334171
Cardiac arrest	145.23	22.28	203	16158	88859	31592124
Fear	128.53	22.28	74	16287	9900	31671083
Ascites	127.48	22.28	130	16231	40883	31640100
Propofol infusion syndrome	119.36	22.28	35	16326	800	31680183
Respiratory failure	111.73	22.28	193	16168	101256	31579727
Toxic epidermal necrolysis	110.80	22.28	87	16274	19437	31661546
Acute kidney injury	104.72	22.28	349	16012	279365	31401618
Fatigue	104.30	22.28	23	16338	335183	31345800
Injury	101.56	22.28	83	16278	19626	31661357
Renal injury	98.62	22.28	64	16297	10601	31670382
Haemodynamic instability	95.74	22.28	58	16303	8517	31672466
Abdominal distension	95.40	22.28	124	16237	50560	31630423
Renal failure	92.04	22.28	199	16162	123131	31557852
Anhedonia	87.40	22.28	52	16309	7390	31673593
Rhabdomyolysis	86.24	22.28	133	16228	63448	31617535
Vasoplegia syndrome	83.76	22.28	32	16329	1681	31679302
Emotional distress	81.50	22.28	64	16297	14292	31666691
Lactic acidosis	79.41	22.28	90	16271	31847	31649136
Metabolic acidosis	77.86	22.28	99	16262	39478	31641505
Hyponatraemia	76.75	22.28	137	16224	73662	31607321
Diarrhoea	74.62	22.28	45	16316	352364	31328619
Headache	72.48	22.28	6	16355	183646	31497337
Acute respiratory distress syndrome	71.17	22.28	75	16286	24465	31656518
Asthenia	66.66	22.28	17	16344	224738	31456245
Dizziness	63.16	22.28	13	16348	199134	31481849
Unevaluable event	62.53	22.28	78	16283	30497	31650486
Blood phosphorus increased	62.43	22.28	35	16326	4447	31676536
General physical health deterioration	60.73	22.28	161	16200	113274	31567709
Arthralgia	59.58	22.28	5	16356	151419	31529564
Fall	55.30	22.28	14	16347	186075	31494908
Dry gangrene	53.54	22.28	16	16345	391	31680592
Stress cardiomyopathy	51.88	22.28	23	16338	1767	31679216
Myocardial calcification	51.37	22.28	10	16351	32	31680951
Pain in extremity	48.09	22.28	3	16358	116200	31564783
Drug ineffective for unapproved indication	47.40	22.28	52	16309	17738	31663245
Burkholderia test positive	46.08	22.28	18	16343	1004	31679979
Dyspnoea	45.47	22.28	67	16294	343412	31337571
Drug reaction with eosinophilia and systemic symptoms	45.22	22.28	66	16295	29952	31651031
Decreased appetite	44.60	22.28	12	16349	153205	31527778
Renal impairment	44.60	22.28	121	16240	86228	31594755
Pharyngeal haemorrhage	44.43	22.28	16	16345	711	31680272
Anion gap	44.21	22.28	16	16345	721	31680262
Acidosis	43.23	22.28	38	16323	9908	31671075
Hypertransaminasaemia	42.68	22.28	27	16334	4277	31676706
Cholestasis	42.00	22.28	58	16303	25017	31655966
Back pain	41.97	22.28	4	16357	109409	31571574
Hyperdynamic left ventricle	41.92	22.28	11	16350	164	31680819
Overdose	41.10	22.28	116	16245	84548	31596435
Compartment syndrome	40.33	22.28	22	16339	2649	31678334
Diabetes insipidus	38.57	22.28	21	16340	2519	31678464
Electrocardiogram QRS complex prolonged	38.16	22.28	25	16336	4204	31676779
Malaise	37.72	22.28	20	16341	168491	31512492
Bradycardia	37.65	22.28	99	16262	69228	31611755
Heparin-induced thrombocytopenia	37.54	22.28	27	16334	5279	31675704
Coma	37.22	22.28	72	16289	41078	31639905
Pruritus	36.04	22.28	10	16351	125157	31555826
Rash	35.64	22.28	31	16330	201455	31479528
Peripheral ischaemia	35.30	22.28	26	16335	5274	31675709
Electrocardiogram QT prolonged	35.01	22.28	67	16294	37920	31643063
Ventricular tachycardia	32.67	22.28	50	16311	23651	31657332
Pulseless electrical activity	31.87	22.28	27	16334	6700	31674283
Angle closure glaucoma	30.77	22.28	13	16348	888	31680095
Pulse absent	30.56	22.28	24	16337	5353	31675630
Gait disturbance	29.27	22.28	3	16358	77492	31603491
Hyperthermia malignant	29.01	22.28	16	16345	1968	31679015
Toxicity to various agents	27.62	22.28	174	16187	181313	31499670
Cough	27.33	22.28	18	16343	134796	31546187
Laryngomalacia	27.01	22.28	9	16352	316	31680667
Intestinal ischaemia	26.85	22.28	25	16336	7020	31673963
Oliguria	26.77	22.28	26	16335	7691	31673292
Insomnia	26.51	22.28	8	16353	94828	31586155
Chest pain	25.98	22.28	14	16347	116943	31564040
Blood pressure decreased	25.41	22.28	68	16293	48023	31632960
Dehydration	25.39	22.28	15	16346	119096	31561887
Distributive shock	25.13	22.28	12	16349	1093	31679890
Disseminated intravascular coagulation	25.09	22.28	41	16320	20496	31660487
Cholangiolitis	24.81	22.28	5	16356	20	31680963
Coma scale abnormal	24.20	22.28	18	16343	3705	31677278
Condition aggravated	24.17	22.28	156	16205	163853	31517130
Symmetrical drug-related intertriginous and flexural exanthema	24.09	22.28	8	16353	278	31680705
Coagulopathy	24.03	22.28	38	16323	18477	31662506
Product use in unapproved indication	23.92	22.28	108	16253	99063	31581920
COVID-19 pneumonia	23.83	22.28	31	16330	12624	31668359
Pneumonia acinetobacter	23.48	22.28	6	16355	80	31680903
Hypercapnia	23.17	22.28	18	16343	3953	31677030
Abdominal pain upper	22.87	22.28	3	16358	63999	31616984
Nasopharyngitis	22.51	22.28	3	16358	63242	31617741
Serotonin syndrome	22.29	22.28	37	16324	18736	31662247

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	853.48	20.83	539	28585	107976	70791344
Cardiogenic shock	656.31	20.83	313	28811	35994	70863326
Drug ineffective	561.33	20.83	1202	27922	938550	69960770
Septic shock	490.96	20.83	390	28734	111868	70787452
Shock	467.46	20.83	258	28866	40167	70859153
Hypotension	436.54	20.83	671	28453	403710	70495610
Cardiac arrest	383.28	20.83	396	28728	159438	70739882
Appendicolith	324.17	20.83	112	29012	5568	70893752
Metabolic acidosis	247.63	20.83	221	28903	74125	70825195
Fatigue	239.88	20.83	29	29095	824290	70075030
Sepsis	238.31	20.83	388	28736	244157	70655163
Ventricular fibrillation	236.07	20.83	144	28980	26967	70872353
Respiratory failure	218.77	20.83	306	28818	168429	70730891
Appendicitis	216.10	20.83	115	29009	16618	70882702
Acute kidney injury	213.52	20.83	546	28578	474078	70425242
Propofol infusion syndrome	202.55	20.83	59	29065	1670	70897650
Renal failure	200.57	20.83	312	28812	188758	70710562
Haemodynamic instability	197.67	20.83	106	29018	15552	70883768
Stress	189.47	20.83	183	28941	67783	70831537
Stress cardiomyopathy	187.10	20.83	88	29036	9774	70889546
Vasoplegia syndrome	186.94	20.83	64	29060	3092	70896228
Renal injury	183.90	20.83	102	29022	15992	70883328
Off label use	176.62	20.83	685	28439	742375	70156945
Lactic acidosis	173.61	20.83	171	28953	64853	70834467
Headache	164.71	20.83	22	29102	580383	70318937
Acute respiratory distress syndrome	164.47	20.83	136	28988	41118	70858202
Peripheral ischaemia	156.51	20.83	75	29049	8683	70890637
Fear	154.67	20.83	100	29024	20711	70878609
Arthralgia	150.39	20.83	16	29108	503374	70395946
Intentional overdose	141.78	20.83	188	28936	98247	70801073
Dry gangrene	134.28	20.83	37	29087	852	70898468
Ventricular tachycardia	124.60	20.83	110	29014	36313	70863007
Electrocardiogram QRS complex prolonged	122.68	20.83	66	29058	9740	70889580
Myoglobin urine present	122.33	20.83	33	29091	700	70898620
Pulseless electrical activity	119.65	20.83	72	29052	13143	70886177
Pharyngeal haemorrhage	117.07	20.83	36	29088	1231	70898089
Toxicity to various agents	115.65	20.83	382	28742	381790	70517530
Anhedonia	114.82	20.83	72	29052	14141	70885179
Fall	112.17	20.83	23	29101	444073	70455247
Ascites	111.37	20.83	138	28986	67409	70831911
Diarrhoea	108.04	20.83	98	29026	783243	70116077
Renal impairment	106.95	20.83	203	28921	143734	70755586
Bradycardia	106.84	20.83	187	28937	124428	70774892
Dizziness	105.56	20.83	30	29094	464111	70435209
Serotonin syndrome	100.01	20.83	104	29020	42010	70857310
Rhabdomyolysis	98.54	20.83	156	28968	95604	70803716
Toxic epidermal necrolysis	98.12	20.83	100	29024	39457	70859863
Circulatory collapse	97.82	20.83	95	29029	35379	70863941
Weight decreased	94.87	20.83	9	29115	310479	70588841
Pain in extremity	93.95	20.83	12	29112	328070	70571250
Pruritus	93.46	20.83	15	29109	345545	70553775
Unevaluable event	93.35	20.83	111	29013	51952	70847368
Injury	92.95	20.83	124	29000	65121	70834199
Overdose	92.76	20.83	211	28913	169534	70729786
Drug ineffective for unapproved indication	91.20	20.83	95	29029	38443	70860877
Acidosis	89.48	20.83	68	29056	18195	70881125
Hyperlactacidaemia	89.30	20.83	43	29081	5029	70894291
Diabetes insipidus	86.50	20.83	41	29083	4630	70894690
Rash	84.19	20.83	53	29071	510509	70388811
Emotional distress	81.49	20.83	88	29036	37100	70862220
Blood phosphorus increased	80.33	20.83	44	29080	6726	70892594
Back pain	77.42	20.83	10	29114	271142	70628178
Malaise	76.95	20.83	41	29083	432891	70466429
Weight increased	76.80	20.83	6	29118	242325	70656995
Electrocardiogram QT prolonged	72.41	20.83	126	28998	83391	70815929
Extremity necrosis	71.10	20.83	31	29093	2883	70896437
Compartment syndrome	69.92	20.83	35	29089	4451	70894869
Nasopharyngitis	69.04	20.83	6	29118	222200	70677120
Dyspnoea	68.60	20.83	133	28991	769927	70129393
Disseminated intravascular coagulation	67.55	20.83	76	29048	33522	70865798
Asthenia	66.89	20.83	54	29070	457612	70441708
Pulmonary oedema	66.01	20.83	120	29004	82158	70817162
Alopecia	65.55	20.83	4	29120	198486	70700834
Tachycardia	65.35	20.83	177	28947	158369	70740951
Electrocardiogram ST segment elevation	65.16	20.83	40	29084	7564	70891756
Myocardial calcification	64.71	20.83	12	29112	37	70899283
Abdominal discomfort	63.52	20.83	7	29117	214651	70684669
Cholestasis	60.66	20.83	86	29038	47786	70851534
Drug intolerance	60.52	20.83	10	29114	225677	70673643
Coma	60.25	20.83	123	29001	91721	70807599
Abdominal distension	59.23	20.83	132	28992	104537	70794783
Oliguria	58.67	20.83	49	29075	15002	70884318
Hyperdynamic left ventricle	58.54	20.83	16	29108	357	70898963
Decreased appetite	58.46	20.83	26	29098	304754	70594566
Atrioventricular block first degree	58.37	20.83	44	29080	11629	70887691
Peripheral swelling	58.11	20.83	13	29111	236550	70662770
Sinusitis	57.12	20.83	3	29121	169192	70730128
Heparin-induced thrombocytopenia	56.47	20.83	39	29085	8998	70890322
Toxic encephalopathy	56.01	20.83	41	29083	10365	70888955
Distributive shock	55.24	20.83	24	29100	2213	70897107
Left ventricle outflow tract obstruction	55.21	20.83	15	29109	327	70898993
Ventricular hypokinesia	55.02	20.83	37	29087	8175	70891145
Coagulopathy	54.88	20.83	68	29056	33181	70866139
Anuria	54.86	20.83	53	29071	19600	70879720
Activated partial thromboplastin time prolonged	54.79	20.83	45	29079	13460	70885860
Cardiotoxicity	53.75	20.83	41	29083	11029	70888291
Intestinal ischaemia	52.75	20.83	42	29082	12022	70887298
Blood pressure decreased	52.44	20.83	116	29008	91399	70807921
Gait disturbance	52.39	20.83	7	29117	185099	70714221
Nausea	52.10	20.83	178	28946	851910	70047410
Hyponatraemia	51.84	20.83	164	28960	159923	70739397
Hypersensitivity	50.08	20.83	16	29108	229796	70669524
Insomnia	49.57	20.83	14	29110	217792	70681528
Muscle spasms	48.27	20.83	4	29120	154042	70745278
Hypoaesthesia	48.15	20.83	4	29120	153735	70745585
Cough	47.98	20.83	38	29086	325339	70573981
Blood pressure increased	47.02	20.83	10	29114	188507	70710813
Hyperkalaemia	46.94	20.83	122	29002	106469	70792851
Abdominal pain upper	46.82	20.83	11	29113	193591	70705729
Pulse absent	46.28	20.83	35	29089	9295	70890025
Anion gap	45.97	20.83	20	29104	1850	70897470
Cardiovascular insufficiency	44.44	20.83	22	29102	2731	70896589
Amylase increased	43.49	20.83	35	29089	10173	70889147
Swelling	43.12	20.83	12	29112	188527	70710793
COVID-19 treatment	42.37	20.83	13	29111	441	70898879
Torsade de pointes	41.67	20.83	44	29080	18072	70881248
General physical health deterioration	41.27	20.83	199	28925	235832	70663488
Infusion related reaction	40.87	20.83	15	29109	197519	70701801
Renal tubular necrosis	40.85	20.83	49	29075	23122	70876198
Paraesthesia	40.02	20.83	6	29118	145531	70753789
Myalgia	39.69	20.83	10	29114	167882	70731438
Alanine aminotransferase increased	39.69	20.83	142	28982	147338	70751982
Troponin increased	39.37	20.83	41	29083	16573	70882747
Hypoxia	39.22	20.83	105	29019	93239	70806081
Reversible cerebral vasoconstriction syndrome	39.07	20.83	20	29104	2665	70896655
Cardio-respiratory arrest	38.10	20.83	109	29015	100568	70798752
Acid base balance abnormal	37.24	20.83	11	29113	327	70898993
Hypertransaminasaemia	36.70	20.83	30	29094	8913	70890407
Drug reaction with eosinophilia and systemic symptoms	36.04	20.83	76	29048	57937	70841383
Cardiomyopathy	35.82	20.83	49	29075	26324	70872996
Drug hypersensitivity	35.81	20.83	33	29091	262426	70636894
Respiratory gas exchange disorder	35.67	20.83	13	29111	755	70898565
Hepatic failure	35.23	20.83	75	29049	57550	70841770
Burkholderia test positive	35.20	20.83	12	29112	572	70898748
Ischaemic hepatitis	35.04	20.83	20	29104	3309	70896011
Mydriasis	34.98	20.83	38	29086	16115	70883205
Therapeutic product effect decreased	34.82	20.83	8	29116	143010	70756310
Injection site pain	34.37	20.83	4	29120	117615	70781705
Systolic dysfunction	34.31	20.83	20	29104	3441	70895879
Bronchitis	34.22	20.83	4	29120	117239	70782081
Stomatitis	33.76	20.83	6	29118	128505	70770815
Asthma	33.16	20.83	5	29119	120788	70778532
Inappropriate schedule of product administration	33.13	20.83	3	29121	107552	70791768
Thrombocytopenia	33.11	20.83	189	28935	238921	70660399
Urticaria	32.69	20.83	13	29111	163036	70736284
Wrong product administered	32.16	20.83	27	29097	8324	70890996
Electrocardiogram ST segment depression	31.93	20.83	21	29103	4470	70894850
Completed suicide	31.65	20.83	28	29096	227107	70672213
Nervous system disorder	31.50	20.83	44	29080	24102	70875218
Diabetic macroangiopathy	31.16	20.83	8	29116	139	70899181
Erythema	31.08	20.83	22	29102	199541	70699779
Confusional state	30.91	20.83	43	29081	284355	70614965
Arteriospasm coronary	30.77	20.83	23	29101	6001	70893319
Hyperthermia malignant	30.76	20.83	17	29107	2644	70896676
Unmasking of previously unidentified disease	30.53	20.83	15	29109	1832	70897488
Chest pain	30.41	20.83	35	29089	251225	70648095
Condition aggravated	30.31	20.83	288	28836	427347	70471973
Dehydration	30.18	20.83	29	29095	226113	70673207
Contraindicated product administered	29.97	20.83	9	29115	134603	70764717
Lower respiratory tract infection	29.89	20.83	5	29119	111908	70787412
Pain	29.76	20.83	145	28979	628671	70270649
Contusion	29.55	20.83	8	29116	128028	70771292
Muscular weakness	29.47	20.83	10	29114	138326	70760994
Neuropathy peripheral	29.15	20.83	8	29116	126888	70772432
Mobility decreased	28.88	20.83	4	29120	102995	70796325
Coma scale abnormal	28.72	20.83	25	29099	8091	70891229
COVID-19 pneumonia	28.61	20.83	40	29084	21929	70877391
Acute respiratory failure	28.47	20.83	66	29058	53599	70845721
Mean arterial pressure increased	27.30	20.83	6	29118	51	70899269
Leukocytosis	27.03	20.83	54	29070	39614	70859706
Brain death	26.96	20.83	20	29104	5158	70894162
Premature delivery	26.58	20.83	38	29086	21266	70878054
Influenza	26.43	20.83	7	29117	113693	70785627
Oropharyngeal pain	26.40	20.83	4	29120	96306	70803014
Vasoconstriction	26.30	20.83	10	29114	654	70898666
Pneumonia acinetobacter	26.06	20.83	7	29117	146	70899174
Necrosis	25.58	20.83	24	29100	8557	70890763
Respiratory distress	25.54	20.83	64	29060	54586	70844734
Suicide attempt	25.29	20.83	81	29043	79429	70819891
Electrocardiogram P wave abnormal	25.15	20.83	8	29116	306	70899014
Cholangiolitis	25.04	20.83	5	29119	25	70899295
Product use in unapproved indication	24.88	20.83	158	28966	207320	70692000
Blood creatine phosphokinase increased	24.81	20.83	68	29056	61195	70838125
Herpes zoster	24.65	20.83	3	29121	85232	70814088
Blood creatinine increased	24.55	20.83	120	29004	142881	70756439
Loss of personal independence in daily activities	24.52	20.83	3	29121	84907	70814413
Blood lactate dehydrogenase increased	24.16	20.83	48	29076	35079	70864241
Balance disorder	24.13	20.83	4	29120	90124	70809196
Procedural hypotension	23.94	20.83	13	29111	1953	70897367
Pseudomonas infection	23.87	20.83	34	29090	18960	70880360
Urinary tract infection	23.79	20.83	41	29083	248728	70650592
Catheter site haemorrhage	23.69	20.83	18	29106	4813	70894507
Palpitations	23.60	20.83	8	29116	110745	70788575
Ventricular arrhythmia	23.53	20.83	22	29102	7808	70891512
Vasodilatation	23.33	20.83	15	29109	3073	70896247
Product contamination microbial	23.31	20.83	10	29114	894	70898426
Chest discomfort	23.21	20.83	11	29113	124370	70774950
Memory impairment	22.91	20.83	5	29119	92636	70806684
Hypoxic-ischaemic encephalopathy	22.87	20.83	21	29103	7287	70892033
Infection	22.76	20.83	32	29092	210753	70688567
Gangrene	22.42	20.83	22	29102	8287	70891033
Gastrointestinal disorder	21.80	20.83	8	29116	105419	70793901
Hypothermia	21.78	20.83	34	29090	20560	70878760
Supraventricular tachycardia	21.49	20.83	33	29091	19677	70879643
Cardiac dysfunction	21.48	20.83	15	29109	3522	70895798
Electrocardiogram repolarisation abnormality	21.41	20.83	12	29112	1917	70897403
Central nervous system injury	21.04	20.83	6	29118	157	70899163

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA03	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
FDA CS	M0003647	Catecholamines
FDA EPC	N0000175570	Catecholamine
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D000316	Adrenergic alpha-Agonists
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D013566	Sympathomimetics
MeSH PA	D014662	Vasoconstrictor Agents
CHEBI has role	CHEBI:25512	neurotransmitters
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:35569	alpha-adrenergic agonists
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76967	human xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bronchiectasis	indication	12295008	DOID:9563
Bronchitis	indication	32398004	DOID:6132
Low blood pressure	indication	45007003
Pulmonary emphysema	indication	87433001
Asthma	indication	195967001	DOID:2841
Asthma management	indication	406162001
Acute exacerbation of asthma	indication	708038006
Hypovolemia	contraindication	28560003
Hypercapnia	contraindication	29596007
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypoxia	contraindication	389086002
Thrombosis	contraindication	439127006
Occlusive Vascular Disease	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.41	acidic
pKa2	12.03	acidic
pKa3	12.63	acidic
pKa4	8.83	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	10226436	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	10420735	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	11413259	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	10226436	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	10420735	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	11413259	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	10226436	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	10420735	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	NEVAKAR INJECTABLES	N214628	Oct. 6, 2022	RX	SOLUTION	INTRAVENOUS	11413259	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	AGONIST	Ki	7.20	CHEMBL	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	AGONIST	Ki	5.82	CHEMBL	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	AGONIST	Ki	7.40	IUPHAR	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	AGONIST	Ki	4.69	CHEMBL	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	Kd	5.40	CHEMBL	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	AGONIST	Ki	7.18	CHEMBL	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	Ki	6	IUPHAR	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Kd	4.30	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.89	CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.48	PDSP
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.37	PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.07	PDSP
Mu-type opioid receptor	GPCR		OPRM_RAT		Ki	4.85	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_BOVIN		Ki	5.22	CHEMBL
Beta-1 adrenergic receptor	GPCR		ADRB1_RAT		Ki	6.90	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CANFA		Ki	5.30	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		Ki	6.35	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_RAT		Ki	5.38	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_MESAU		Ki	6.58	CHEMBL
Beta-1 adrenergic receptor	GPCR		B0FL73_CAVPO		Ki	6.40	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	8.32	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		Ki	6.41	CHEMBL
Adrenergic receptor alpha	GPCR		ADA1B_RAT ADA2B_RAT ADA2C_RAT ADA2A_RAT ADA1D_RAT ADA1A_RAT		IC50	7.80	CHEMBL
Adrenergic receptor beta	GPCR		ADRB2_RAT ADRB1_RAT ADRB3_RAT		IC50	6	CHEMBL
Alpha-2C adrenergic receptor	GPCR		ADA2C_MOUSE		Ki	6.19	CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_MOUSE		Ki	5.24	CHEMBL
Alpha-2B adrenergic receptor	GPCR		ADA2B_RAT		Ki	7.11	CHEMBL

External reference:

ID	Source
4019859	VUID
N0000147945	NUI
D00076	KEGG_DRUG
108341-18-0	SECONDARY_CAS_RN
4018242	VANDF
4019859	VANDF
C0028351	UMLSCUI
CHEBI:33569	CHEBI
LT4	PDB_CHEM_ID
CHEMBL1434513	ChEMBL_ID
CHEMBL1437	ChEMBL_ID
DB00368	DRUGBANK_ID
CHEMBL1356607	ChEMBL_ID
D009638	MESH_DESCRIPTOR_UI
439260	PUBCHEM_CID
33	INN_ID
484	IUPHAR_LIGAND_ID
X4W3ENH1CV	UNII
7508	RXNORM
2706	MMSL
333906	MMSL
35060	MMSL
5186	MMSL
NOCODE	MMSL
d00323	MMSL
001777	NDDF
004718	NDDF
111130009	SNOMEDCT_US
45555007	SNOMEDCT_US
77673009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9318	INJECTION	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0108	INJECTION, SOLUTION	8 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0108	INJECTION, SOLUTION	8 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0108	INJECTION, SOLUTION	8 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0112	INJECTION, SOLUTION	4 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0112	INJECTION, SOLUTION	4 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0112	INJECTION, SOLUTION	4 mg	INTRAVENOUS	NDA	24 sections
Levophed	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1443	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	20 sections
Levophed	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1443	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	20 sections
LEVOPHED	Human prescription drug label	1	0409-3375	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	27 sections
LEVOPHED	Human prescription drug label	1	0409-3375	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	27 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-1153	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-1153	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3755	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3755	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3755	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-316	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	25 sections
Norepinephrine bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	36000-162	INJECTION	1 mg	INTRAVENOUS	ANDA	18 sections
Norepinephrine bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	36000-162	INJECTION	1 mg	INTRAVENOUS	ANDA	18 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	43066-997	INJECTION	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-640	INJECTION, SOLUTION, CONCENTRATE	0.02 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-641	INJECTION, SOLUTION, CONCENTRATE	0.03 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-642	INJECTION, SOLUTION, CONCENTRATE	0.06 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	Human Prescription Drug Label	1	47335-615	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
LEVOPHED(R) NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1315	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	12 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1528	INJECTION	1 mg	INTRAVENOUS	ANDA	16 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1528	INJECTION	1 mg	INTRAVENOUS	ANDA	16 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	51991-983	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	25 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	52533-164	INJECTION, SOLUTION	64 ug	INTRAVENOUS	unapproved drug other	7 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	52533-165	INJECTION, SOLUTION	16 ug	INTRAVENOUS	unapproved drug other	7 sections